Skip to main content
. 2013 Nov;57(11):5559–5564. doi: 10.1128/AAC.00500-13

Fig 5.

Fig 5

Assessment of lung inflammation and injury following P. aeruginosa infection and treatment with 100 μg wild-type or engineered lysozyme. (A) BALF immune cell concentration (n = 5 mice per group; ANOVA, P = 0.067); (B) BALF protein concentration as a surrogate of lung injury (n = 5 mice per group; ANOVA, P = 0.008); (C) BALF cytokine KC concentration as a marker of inflammation (n = 6 mice per group; ANOVA, P = 0.040); (D) BALF TNF-α concentration as a marker of inflammation (n = 6 mice per group; ANOVA, P = 0.039). The means ± SEMs are indicated. *, P < 0.05 compared with the PBS control group; **, P < 0.01 compared with the PBS control group.